Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

FDA Approves 2 Pain Drugs & New Gout Treatment on Road to Approval

Michele B. Kaufman, PharmD, BCGP  |  November 18, 2015

The FDA has approved two drugs designed to manage pain: buprenorphine for chronic pain and meloxicam capsules for OA pain. Lesurinad is also closer to FDA approval for treating gout…

Obama Nominee to Lead FDA Defends Drug Industry Ties

Toni Clarke  |  November 17, 2015

(Reuters)—President Barack Obama’s nominee to head the U.S. Food and Drug Administration defended his ties to the pharmaceutical industry on Tuesday during a Senate committee hearing that included questions on soaring drug prices. Presidential candidate Bernie Sanders was among the Democrats who grilled Dr. Robert Califf (64), who joined the FDA in January as a…

WHO Warns of Widespread Misunderstanding of Superbug Threat

Kate Kelland  |  November 17, 2015

LONDON (Reuters)—People across the world are confused about the major threat to public health posed by drug-resistant superbugs and do not know how to stop that risk growing, the World Health Organization (WHO) said on Monday. Ramping up its fight against antibiotic resistance with a survey of public awareness, the United Nations health agency said…

U.S. Drug Benefit Managers Clamp Down on Specialty Pharmacies

Caroline Humer & Deena Beasley  |  November 17, 2015

NEW YORK/LOS ANGELES (Reuters)—In recent days, the largest U.S. managers of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices, officials at the benefit managers told Reuters. The terminations come from payers who together manage drug benefits for…

Bronchial Tissue Immune Activation Seen in Early Rheumatoid Arthritis

Reuters Staff  |  November 17, 2015

NEW YORK (Reuters Health)—Patients with untreated early rheumatoid arthritis (RA) show signs of immune activation and local inflammation in their bronchial tissues, researchers from Sweden report. Previous studies have shown that patients with RA have shared citrullinated epitopes in the lungs and joints, as well as anticitrullinated protein antibodies (ACPA) in bronchoalveolar lavage (BAL), suggesting…

Does Methotrexate Increase Skin Cancer Risk?

Lara C. Pullen, PhD  |  November 16, 2015

A recent study connects the use of immunosuppressant and biologic agents to an increased risk of nonmelanoma skin cancer in patients being treated for RA and IBD…

Patients OK with Secure Web Portals for Test Results

Lisa Rapaport  |  November 15, 2015

(Reuters Health)—Of all the ways for patients to receive their medical test results, one option—password-protected websites—appears to be preferred much of the time, a study suggests. U.S. researchers surveyed about 400 adults and found they were generally comfortable with web portals regardless of how sensitive the test results might be. This was among the most…

Higher Tocilizumab Dose Plus Methotrexate Best for Early RA

Reuters Staff  |  November 14, 2015

NEW YORK (Reuters Health)—Tocilizumab improves remission rates and slows disease progression in patients with early rheumatoid arthritis (RA), a new randomized controlled trial demonstrates. Tocilizumab was effective both on its own and when combined with methotrexate, Dr. Gerd R. Burmester of Charite Medical University of Berlin and his colleagues found. Tocilizumab, an interleukin-6 (IL-6) blocker,…

Expert Q&A: Dr. Michael Lockshin on APS

Richard Quinn  |  November 13, 2015

Michael Lockshin, MD, reminds medical professionals that patients suffering from antiphospholipid syndrome (APS) don’t respond to medications in the same way as patients with other clotting-related diseases. Insufficient evidence exists to determine whether the new wave of anticoagulant medications is safe for use in patients with APS…

Early Probiotics Supplementation Tied to Lower Risk of Islet Autoimmunity

Will Boggs, MD  |  November 12, 2015

NEW YORK (Reuters Health)—Exposure to probiotics in the first few weeks of life is associated with a reduced risk of islet autoimmunity, according to results from the TEDDY study. “Early supplementation of probiotics may be important but we need more research on this,” Dr. Ulla Uusitalo from University of South Florida in Tampa told Reuters…

  • « Previous Page
  • 1
  • …
  • 279
  • 280
  • 281
  • 282
  • 283
  • …
  • 322
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences